gms | German Medical Science

63rd Annual Meeting of the German Society of Neurosurgery (DGNC)
Joint Meeting with the Japanese Neurosurgical Society (JNS)

German Society of Neurosurgery (DGNC)

13 - 16 June 2012, Leipzig

IDH 1/2 mutations in astrocytomas WHO grade II: association with localization and seizure as initial symptom

Meeting Abstract

  • F. Stockhammer - Klinik für Neurochirurgie, Universitätsmedizin Göttingen; Klinik für Neurochirurgie, Universitätsmedizin Rostock
  • M. Misch - Klinik für Neurochirurgie, Charité - Universitätsmedizin Berlin
  • H.J. Helms - Abteilung für medizinische Statistik, Universitätsmedizin Göttingen
  • U. Lengler - Klinik für Psychiatrie, Universität Leipzig
  • F. Prall - Institut für Pathologie, Universitätsmedizin Göttingen
  • A.V. Deimling - Institut für Neuropathologie, Ruprecht-Karls-Universität Heidelberg; Klinische Kooperationseinheit G380, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland
  • C. Hartmann - Institut für Neuropathologie, Ruprecht-Karls-Universität Heidelberg; Klinische Kooperationseinheit G380, Deutsches Krebsforschungszentrum, Heidelberg, Deutschland

Deutsche Gesellschaft für Neurochirurgie. Japanische Gesellschaft für Neurochirurgie. 63. Jahrestagung der Deutschen Gesellschaft für Neurochirurgie (DGNC), Joint Meeting mit der Japanischen Gesellschaft für Neurochirurgie (JNS). Leipzig, 13.-16.06.2012. Düsseldorf: German Medical Science GMS Publishing House; 2012. DocFR.01.01

DOI: 10.3205/12dgnc165, URN: urn:nbn:de:0183-12dgnc1652

Published: June 4, 2012

© 2012 Stockhammer et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: Seizures are the most common initial symptom in patients with low-grade gliomas and strongly depend on the site of the tumour. The majority of low-grade gliomas reveal mutations in the genes encoding isocitrate-dehydrogenase 1 (IDH1) or 2 (IDH2). These mutations are associated with metabolic changes that might have epileptogenic potential. We investigated the correlation of IDH1/2 mutations with localization of the tumour and seizures as initial symptoms.

Methods: Patients with astrocytoma WHO grade II, cortical infiltration, filed initial symptom and available tissue for IDH1/2 analysis were included in this retrospective study. IDH1/2 mutation analysis was performed by direct sequencing or by immunohistochemistry with an antibody detecting mutated protein IDH1 R132H. In case of negative immunohistochemistry, sequencing was performed. IDH1/2 status was defined as mutated, if any of these investigations were positive.

Results: Seventy-nine patients were included. IDH1 or IDH2 mutation was present in 63 (80%) patients, which were in the mean younger than patients without IDH1/2 mutation (40 vs. 47 years, p = 0.0331, t-test). IDH1/2 mutations were associated to frontal tumour location (p = 0.0202). All 12 tumours in the insula revealed IDH1/2 mutations. Seizure as initial symptom was recorded in 57 (72%) patients and was associated with IDH1 or IDH2 mutation by multivariate analysis (OR 22.563, p = 0.0019).

Conclusions: In astrocytomas WHO grade II IDH1/2 mutations mostly occur in tumours infiltrating the frontal lobe. Seizure as initial symptom is associated with IDH1 or IDH2 mutation.